Palvella at Stifel 2026 Healthcare Conference: launch plans take shape
At a glance
- $PVLA today−1.40%last $142.58
- Vs industry peers−0.95 pts6-peer median −0.44% · behind
- Since Nov 10−13.9%from the first trade after the story
- 52-week range20.8% below high$72.23 – $179.95
- Cash runway~3.8 yrs$193.3M cash ÷ $4.3M/mo burn · 10-Q
- Coverage9 this week20 in 30 days · 1.9× its usual pace
Nothing reported about palvella across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Drugmakers' futures hinge on what's in their late-stage trials — not just quarterly earnings — as investors eye the next big breakthrough.
- How the stocks are trading: $PVLA -1.40%, $SF -1.51%, $HR -0.87% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Palvella Therapeutics ($PVLA) fell 1.40% to $142.58 in the latest session. Over the past month it is up 16.0%. It now sits 21% under the 52-week high of $179.95 and 97% above the year's low of $72.23. The year's high was 2.5 times its low, which makes double-digit swings fairly routine here. Stifel Financial ($SF) declined 1.51% to $71.50 in the latest session. Over the past month it is up 7.5%. That leaves it 20% below its 52-week high of $89.83 and 9.3% above its low of $65.40. The high sits 37% above the low, a moderate range for a year.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $PVLA lost $24.6M over the quarter to Sep 30, 2026. Operations used $38.1M of cash over the nine months to Sep 30, 2026 — about $4.3M a month — against $193.3M in cash on Sep 30, 2026. At that pace the cash covers about 3.8 years. Total liabilities were $41.5M against $193.3M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Nov 5, 2026, 8-K on Nov 5, 2026, 8-K on Oct 28, 2026. Figures are as filed with the SEC; the $PVLA page has the full statements.
How much coverage it is getting
Wook has filed 20 stories on these companies in the last 30 days, 9 of them this week. That is running well ahead of normal: over the month it has averaged about 5 a week. Going by their wording, 25% read bullish, 75% neutral and 0% bearish. This one reads neutral, like most of them. Investing.com wrote 11 of the 20 (55%), so the count reflects one outlet's output more than broad attention.
The bigger picture
Healthcare news swings on FDA decisions, trial results, and pricing changes — one event can shift a company's fate, while broader policy shifts ripple across the sector. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $PVLA page, and they say what management has disclosed without a reporter in between. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. Wook AI, at the top of the page, can work out how far $PVLA is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 10, 2026. $PVLA has moved -13.88% ($165.55 to $142.58), $SF has moved -2.10% ($73.03 to $71.50) and $HR has moved -0.17% ($19.18 to $19.15). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
